title: ÐÑÐµÐ½ÐºÐ° Ð±Ð¸Ð¾ÑÐ°ÑÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ Ð¸ Ð´Ð¾Ð· Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð²,Ð¿ÑÐ¾Ñ Ð¾Ð´ÑÑÐ¸Ñ ÑÐµÑÐ°Ð½Ð¾ÑÑÐ¸ÐºÑ c ÑÑÐ°ÑÑÑÐ·ÑÐ¼Ð°Ð±Ð¾Ð¼, Ð¼ÐµÑÐµÐ½Ð½ÑÐ¼ 89zr Ð¸ 177lu
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: The estimation of biodistribution and doses of patients undertringing theranostic with trastuzumab labeled with 89ZR and 177LU
Creators: name: ÐÐ°Ð²ÑÐµÑÐ¾Ð², ÐÐ¼Ð¸ÑÑÐ¸Ð¹
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2021
Subjects: ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ°
ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ
Ð¼Ð¾Ð½Ð¾ÐºÐ»Ð¾Ð½Ð°Ð»ÑÐ½ÑÐµ Ð°Ð½ÑÐ¸ÑÐµÐ»Ð°
Ð¿ÐµÐ¿ÑÐ¸Ð´Ñ
Ð»ÑÑÐµÑÐ¸Ð¹
ÑÐ¸ÑÐºÐ¾Ð½Ð¸Ð¹
Ð±Ð¸Ð¾ÑÐ°ÑÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ¾Ð²
ÐºÐ°Ð¼ÐµÑÐ½ÑÐµ Ð¼Ð¾Ð´ÐµÐ»Ð¸
Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ
radionuclide diagnostics
radionuclide therapy
monoclonal antibodies
peptides
luthesium
zirconium
biodistribution of radiopharmaceuticals
compartment models
absorbed dose

description: ÐÑÐ¸ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸Ð¸ ÑÑÐ°ÑÑÑÐ·ÑÐ¼Ð°Ð±Ð° Ñ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð°Ð¼Ð¸ 89Zr Ð´Ð»Ñ Ð¸Ð¼Ð¼ÑÐ½Ð¾Ð¿ÑÑ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ¸ Ð¸ 177Lu Ð´Ð»Ñ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð·Ð»Ð¾ÐºÐ°ÑÐµÑÑÐ²ÐµÐ½Ð½ÑÑ Ð½Ð¾Ð²Ð¾Ð¾Ð±ÑÐ°Ð·Ð¾Ð²Ð°Ð½Ð¸Ð¹ Ð´Ð¾ÑÑÐ¸Ð³Ð°ÐµÑÑÑ Ð¼Ð°ÐºÑÐ¸Ð¼Ð°Ð»ÑÐ½ÑÐ¹ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÑÐµÑÐºÐ¸Ð¹ Ð¸ ÑÐµÑÐ°Ð¿ÐµÐ²ÑÐ¸ÑÐµÑÐºÐ¸Ð¹ ÑÑÑÐµÐºÑ.ÐÑÐ½Ð¾Ð²Ð½Ð°Ñ ÑÐµÐ»Ñ Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÑÐºÐ¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ â Ð½Ð°ÑÑÐ½Ð¾Ðµ Ð¾Ð±Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð¸Ðµ ÑÐµÑÐ°Ð½Ð¾ÑÑÐ¸ÐºÐ¸ Ñ ÑÑÐ°ÑÑÑÐ·ÑÐ¼Ð°Ð±Ð¾Ð¼, Ð¼ÐµÑÐµÐ½Ð½ÑÐ¼ 89Zr Ð¸ 177Lu.Ð ÑÐ°Ð±Ð¾ÑÐµ Ð±ÑÐ» Ð¿ÑÐ¾Ð¸Ð·Ð²ÐµÐ´ÐµÐ½ ÑÐ°ÑÑÐµÑ Ð½Ð°ÐºÐ¾Ð¿Ð»ÐµÐ½Ð½Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ Ð Ð¤Ð Ð´Ð»Ñ Ð¸Ð½ÑÐµÑÐµÑÑÑÑÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð¾Ð² Ñ Ð¼ÑÑÐµÐ¹ Ð² Ð²Ð¸Ð´Ðµ Ð²Ð²ÐµÐ´ÐµÐ½Ð½Ð¾Ð¹ Ð´Ð¾Ð·Ñ (ID) Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼Ð´Ð°Ð½Ð½ÑÑ Ð¸Ð· Ð¿ÑÐ±Ð»Ð¸ÐºÐ°ÑÐ¸Ð¹, Ð² Ð¿ÑÐ¾Ð³ÑÐ°Ð¼Ð¼Ðµ Origin Pro 2020 Ð´Ð»Ñ Ð²Ð²ÐµÐ´ÐµÐ½Ð¸Ñ ÐµÐ´Ð¸Ð½Ð¸ÑÑ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ÐºÐ°ÐºÐ¿Ð»Ð¾ÑÐ°Ð´Ñ Ð¿Ð¾Ð´ ÐºÑÐ¸Ð²Ð¾Ð¹. ÐÐ½ÑÐµÐ³ÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½ÑÐµ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸Ð±ÑÐ»Ð¸ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ñ Ð² Ð¿ÑÐ¾Ð³ÑÐ°Ð¼Ð¼Ðµ IDAC-Dose 2.1 Ð´Ð»Ñ ÑÐ°ÑÑÐµÑÐ° Ð¿Ð¾Ð³Ð»Ð¾ÑÑÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð² Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ð¸ ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾Ð¹ Ð´Ð¾Ð·Ñ ÑÑÐ°Ð½ÑÐ¾Ð¼Ð°Ð²Ð·ÑÐ¾ÑÐ»Ð¾Ð¹ Ð¶ÐµÐ½ÑÐ¸Ð½Ñ. ÐÑÐ»Ð¾ Ð²ÑÑÐ²Ð»ÐµÐ½Ð¾, ÑÑÐ¾ Ð¿ÑÐ¾Ð´ÑÐºÑÑÑÐ°ÑÐ¿Ð°Ð´Ð° 89Zr Ð¸ 177LuÐ½Ðµ Ð²Ð½Ð¾ÑÑÑ ÑÐ²Ð¾Ð¹ Ð²ÐºÐ»Ð°Ð´ Ð² Ð´Ð¾Ð·Ñ , Ñ Ð°Ðº ÐºÐ°Ðº 177LuÑÐ°ÑÐ¿Ð°Ð´Ð°ÐµÑÑÑ Ð´Ð¾ ÑÑÐ°Ð±Ð¸Ð»ÑÐ½Ð¾Ð³Ð¾Ð¸Ð·Ð¾ÑÐ¾Ð¿Ð°177Hf, Ð° Ð²ÐºÐ»Ð°Ð´ Ð² Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ Ð² Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ð¸ ÑÐºÐ°Ð½ÑÑ Ð´Ð»Ñ Ð´Ð¾ÑÐµÑÐ½Ð¸Ñ Ð¸Ð·Ð¾ÑÐ¾Ð¿Ð¾Ð² 89Zr ÑÐ¾ÑÑÐ°Ð²Ð¸Ð» Ð¼ÐµÐ½ÐµÐµ 1 %. ÐÐ°Ð¸Ð±Ð¾Ð»ÑÑÐµÐµ Ð½Ð°ÐºÐ¾Ð¿Ð»ÐµÐ½Ð¸Ðµ 177Lu-ÑÑÐ°ÑÑÑÐ·ÑÐ¼Ð°Ð±Ð½Ð°Ð±Ð»ÑÐ´Ð°ÐµÑÑÑ Ð² Ð¿ÐµÑÐµÐ½Ð¸, ÑÐµÐ»ÐµÐ·ÐµÐ½ÐºÐ¸, ÑÐµÑÐ´ÑÐµ, Ð¿Ð¾ÑÐºÐ°Ñ, ÑÐ¾Ð¾ÑÐ²ÐµÑÑÑÐ²ÐµÐ½Ð½Ð¾ Ð¸ Ð½Ð°Ð¸Ð±Ð¾Ð»ÑÑÐ¸Ðµ Ð¾ÑÐ³Ð°Ð½Ð½ÑÐµ Ð´Ð¾Ð·Ñ Ð±ÑÐ´ÑÑ Ð½Ð°ÐºÐ°Ð¿Ð»Ð¸Ð²Ð°ÑÑÑÑ Ð² ÑÑÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð°Ñ.ÐÐ°ÐºÑÐ¸Ð¼Ð°Ð»ÑÐ½Ð¾Ðµ ÑÐ´ÐµÑÐ¶Ð°Ð½Ð¸Ðµ 89Zr-ÑÑÐ°ÑÑÑÐ·ÑÐ¼Ð°Ð±Ð° Ð½Ð°Ð±Ð»ÑÐ´Ð°Ð»Ð¾ÑÑ Ð² Ð¿ÐµÑÐµÐ½Ð¸,Ð² Ð´ÑÑÐ³Ð¸Ñ Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ð½Ð°ÐºÐ¾Ð¿Ð»ÐµÐ½Ð¸Ðµ Ð±ÑÐ»Ð¾ Ð½Ð¸Ð¶Ðµ , ÑÐµÐ¼ Ð½Ðµ Ð¼ÐµÐ½ÐµÐµ Ð½Ð°Ð±Ð»ÑÐ´Ð°Ð»Ð¾ÑÑ Ð²Ð¾ Ð²ÑÐµÑ Ð¾ÑÐ³Ð°Ð½Ð°Ñ, ÑÑÐ¾ Ð¼Ð¾Ð¶ÐµÑ Ð±ÑÑÑ ÑÐ²ÑÐ·Ð°Ð½Ð¾ÑÐ²ÑÑÐ²Ð¾Ð±Ð¾Ð¶Ð´ÐµÐ½Ð¸ÐµÐ¼ ÑÐ²Ð¾Ð±Ð¾Ð´Ð½Ð¾Ð³Ð¾ 89Zr. Ð¢Ð°ÐºÐ¶Ðµ Ð±ÑÐ»Ð° Ð¾ÑÐ¼ÐµÑÐµÐ½Ð° Ð½Ð¸Ð·ÐºÐ°Ñ ÑÐºÐ¾ÑÐ¾ÑÑÑ Ð²ÑÐ²ÐµÐ´ÐµÐ½Ð¸Ñ Ð¸ Ð¿ÑÐ¸Ð·Ð½Ð°ÐºÐ¸ Ð·Ð°Ð´ÐµÑÐ¶ÐºÐ¸ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ° ÑÐµÐ»ÐµÐ·ÐµÐ½ÐºÐµ, ÑÑÐ¾ Ð¼Ð¾Ð¶ÐµÑ Ð±ÑÑÑ ÑÐ²ÑÐ·Ð°Ð½Ð¾ Ñ Ð¾ÑÐ°Ð¶Ð´ÐµÐ½Ð¸ÐµÐ¼ 89Zr Ð² Ð´Ð°Ð½Ð½Ð¾Ð¼ Ð¾ÑÐ³Ð°Ð½Ðµ.Ð¡Ð°Ð¼ÑÐµ Ð²ÑÑÐ¾ÐºÐ¸Ðµ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ Ð² Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ð¸ ÑÐºÐ°Ð½ÑÑ Ð²ÑÑÐ²Ð»ÐµÐ½Ñ Ñ Ð¿ÐµÑÐµÐ½Ð¸ Ð¸ ÑÐµÑÐ´ÑÐ°.
description: When using trastuzumab with 89Zr radionuclides for immuno-PET diagnostics and 177Lu for the treatment of cancer, the maximum diagnostic and therapeutic effect is achieved. The main goal of the bachelor's work is the scientific substantiation of theranostics with trastuzumab labeled with 89Zr and 177Lu.In this work, the accumulated activity of radiopharmaceuticals for the organs of interest in mice was calculated in the form of the administered dose (ID) using data from publications, in the Origin Pro 2020 program for the introduction of a unit of activity as the area under the curve. Integrated activities were used in the IDAC-Dose 2.1 program to calculate absorbed doses in organs and effective dose in an adult womanphantom. It was revealed that the decay products of 89Zr and 177Lu do not contribute to the doses, since 177Lu decays to the stable isotope 177Hf, and the contribution to the absorbed doses in organs and tissues for the daughter isotopes 89Zr was less than 1%. The maximum accumulation of 177Lu-trastuzumab is observed in the liver, spleen, heart, kidneys, and accordingly, the highest organ doses will accumulate in these organs.The maximum accumulation of 89Zr-trastuzumab was observed in the liver; in other organs, the accumulation was lower; nevertheless, it was observed in all organs, which may be associated with the release of free 89Zr. A low rate of excretion and signs of drug retention in the spleen were also noted, which may be associated with the deposition of 89Zr in this organ. The highest absorbed doses in organs and tissues were found in the liver and hear.